Myelofibrosis

Welcome to the new Myelofibrosis Resource Center! Here you’ll find current information, highlights from the literature, case studies, and other resources that focus on myelofibrosis and the advanced practitioner’s role in delivering high-quality care to patients.

Kate Kennedy, MSN, APRN, ACNP-BC, AOCNP^®

Vanderbilt University Medical Center

Sarah Profitt, PharmD, MMHC, BCOP

Vanderbilt University Medical Center

Myelofibrosis Resource Center

Interview with Somedeb Ball, MD: Disease Basics and the Evolving Treatment Landscape of Myelofibrosis

Blood Cancer United

MPN Research Foundation: Find Support

Blood: Myelofibrosis

Direct and Indirect Costs for Patients with Myeloproliferative Neoplasms

Assessing the Impact of a MPN Diagnosis on Psychosocial Wellness

European Journal of Haematology

Efficacy of momelotinib in myelofibrosis patients: Results from a multicenter study

Blood

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis

Frontiers in Oncology

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: A case report and literature review

Tomography

Fat fraction MRI for longitudinal assessment of bone marrow heterogeneity in a mouse model of myelofibrosis

European Journal of Haematology

Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine

American Journal of Hematology

Impact of donor type on outcomes after allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT

Journal of Hematology

Efficacy and safety of momelotinib in myelofibrosis: A systematic review and meta-analysis with a focus on anemia outcomes

Transplantation and Cellular Therapy

Risk stratification using DIPSS and splenomegaly in myelofibrosis treated with pre-transplant JAK inhibitors

International Journal of Hematology

Efficacy and safety of momelotinib in Janus kinase inhibitor experienced Asian patients with myelofibrosis and anemia

Clinical Lymphoma, Myeloma & Leukemia

Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: A retrospective cohort study

The Management of Myelofibrosis-Related Anemia